Please assess the completion status of the following clinical trial:

Trial Title: Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients:~* Patients aged 45 and over~* Patients from Grade 3 'end of primary schooling minimum (scale Barbizet)~* Non-Metastatic Breast Cancer~* Adjuvant Chemotherapy: FEC, including Docetaxel Protocols~* No major cognitive impairment~* No previous neurological~* Lack of personality disorders and psychiatric disorders evolutionary~* Having signed the informed consent of study participation~Inclusion Criteria for control group:~* Women from the general population aged 45 and over, and matched in age and cultural level in patients~* Topics of Grade 3 'end of primary schooling minimum (scale Barbizet)~* No prior cancer~* No major cognitive impairment~* No previous neurological~* Lack of personality disorders and psychiatric disorders evolutionary~* Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB 2011-A01493-38)(see how the study below) have signed forms no objection and consent to study participation~Exclusion Criteria:~Traduction (français \> anglais)~* Metastatic~* Cancer of the breast other than primitive~* Patients with paraneoplastic syndrome~* Patients under 45 years~* Patients whose achievement is below level 3 'end of primary schooling (scale Barbizet)~* Patients with adjuvant chemotherapy is associated with targeted therapy~* Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)~* Contraindication to the implementation of an MRI (claustrophobia, metal objects in the body)~* disorders of higher functions existing in the administration of chemotherapy~* Neurologic earlier~* Pathology psychiatric evolutionary~* Refusal of participation~* Patients unable to meet the cognitive tests~* Drug use~* Heavy drinking

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patients aged 45 and over group (Type: EXPERIMENTAL): patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
- healthy volunteers (controls) aged 45 and over (Type: ACTIVE_COMPARATOR): healthy volunteers (controls) aged 45 and over

Based on this trial design, predict the completion outcome and termination type (if applicable).